← Back to Search

MV-NIS for Bladder Cancer

Phase 1
Waitlist Available
Research Sponsored by Vyriad, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days after cystectomy
Awards & highlights

Study Summary

This trial is testing a new cancer treatment using a weakened form of the measles virus. The virus is injected into the bladder, where it is hoped it will kill cancer cells. The treatment is given before surgery to remove the bladder.

Eligible Conditions
  • Bladder Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days after cystectomy
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days after cystectomy for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with intravesical MV-NIS treatment related adverse events (NCI CTCAE; Version 4.03)
Secondary outcome measures
Pathologic staging at time of cystectomy following intravesical MV-NIS therapy
pT0 rate at time of cystectomy following intravesical MV-NIS therapy

Side effects data

From 2019 Phase 2 trial • 2 Patients • NCT02192775
100%
Hypokalemia
100%
Neutrophil Count Decreased
100%
C-Reactive Protein Increased
50%
Hypercalcemia
50%
Decreased Respiratory Rate
50%
Apnea
50%
Generalized Muscle Weakness
50%
Lymphocyte Count Decreased
50%
Respiratory Failure
50%
Enterocolitis Infectious
50%
Alterned Mental State
50%
Lactate Increased
50%
Anemia
50%
Sinus Tachycardia
50%
Sepsis
50%
Hypoglycemia
50%
Acidosis (Metabolic)
50%
Hypoxia
50%
Pleural Effusion
50%
Hyperphosphatemia
50%
Localized Edema
50%
Lactate Dehydrogenase Increased
50%
Hypocalcemia
50%
Wheezing
50%
White Blood Count Decreased
50%
Hyperammonia
50%
Hyperglycemia
50%
Hypernatremia
100%
80%
60%
40%
20%
0%
Study treatment Arm
MV-NIS + Cyclophosphamide

Trial Design

1Treatment groups
Experimental Treatment
Group I: Intravesical MV-NIS therapy prior to radical cystectomyExperimental Treatment1 Intervention
MV-NIS will be administered via intravesical instillation as a single dose on Day 1 (7, 14, 21 or 28 days before cystectomy) or two doses on Day 1 and 15 (14 and 28 days before cystectomy).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MV-NIS
2018
Completed Phase 2
~10

Find a Location

Who is running the clinical trial?

Vyriad, Inc.Lead Sponsor
5 Previous Clinical Trials
269 Total Patients Enrolled
Mayo ClinicOTHER
3,204 Previous Clinical Trials
3,768,090 Total Patients Enrolled
Alice Bexon, MDStudy DirectorCMO - Medical Monitor
6 Previous Clinical Trials
477 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy
2018. "Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03171493.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top